Institutional investors, including Capital Research Global Investors and Geode Capital Management, increased their stake in Alnylam Pharmaceuticals, requiring SEC filings.
1 report, 1 independent
Updated Jun 21
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Institutional investors, including Capital Research Global Investors and Geode Capital Management, increased their stake in Alnylam Pharmaceuticals, requiring SEC filings.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Alnylam Pharmaceuticals
biopharmaceutical company
- AstraZeneca's trial failure has created a competitive advantage for Alnylam Pharmaceuticals, which is leveraging AI in its commercial execution.
- Alnylam Pharmaceuticals, SEC, Truist Financial, and Nasdaq were involved in insider trading disclosures, analyst ratings, and stock trading on June 6, 2026.
-
Securities and Exchange Commission
government agency of the Philippines
Related events
- SEC filing tracks institutional investment activity for Xponential Fitness, Inc.
- A company involved in insider transactions and increased investment stakes disclosed filings to the SEC.
- Citadel Advisors acquired a new stake in the NYLIM Candriam U.S. Large Cap Equity ETF, and the SEC was notified on September 1, 2026.
- Ten-League International Holdings Limited filed with the SEC tracking institutional investment.
- Institutional investors file with the Securities and Exchange Commission regarding their holdings involving Nvidia.